**Table 2.**

*Dynamics of the number of EBV DNA copies one month after the end of antiviral therapy in patients with CEBVI.*

From the presented data in the 1st group after Ingaron therapy, only 15 (29.41%) patients had negative PCR results in saliva samples. In the 2nd group of patients taking valaciclovir negative PCR results were obtained in 12 (28.57%) patients. In group 3, one month after taking the combination therapy valganciclovir + Ingaron, 33 (71.74%) patients obtained negative PCR results in saliva samples.

The patients of the 3rd group, according to the combination therapy were distributed as follows:



**Table 3** shows the results obtained in these subgroups.

#### **Table 3.**

*Dynamics of the number of EBV DNA copies one month after the end of combined antiviral therapy in the 3rd group of patients.*

*Recombinant Human Interferon-Gamma: Prospects for the Treatment of Chronic Epstein-Barr… DOI: http://dx.doi.org/10.5772/intechopen.101325*

From the data presented in **Table 2** one can see that in the total 3rd group of patients, there is a reliably positive dynamics of the number of DNA copies the decrease in a month after combination therapy. In subgroup 3A, negative PCR results were obtained in 54.54% of patients. The best result was observed in the patients of subgroup 3B (in 87.50% of patients) who received 20 injections of IFN-γ 500,000 IU every other day, in combination with valganciclovir. That is, the positive result of this therapy regimen is due not so much to the combination of medicines, but to the amount and duration of IFN-γ administration.
